Viridian Therapeutics, Inc. (NASDAQ: VRDN) is a Healthcare company (Biotechnology) with a market capitalization of $3.4B. The Maz Rating grades it against the other companies in its sector.
Viridian Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $30.06, Viridian Therapeutics, Inc. trades at 128.8x sales and 5.8x book value. Over the last twelve months it generated about $27M of revenue and a net loss of $443M. It runs a gross margin of 93.0%, an operating margin of -1781.4% and a net margin of -1724.1%. It shows return on equity of -69.8%, return on invested capital of -48.8% and a free cash flow yield of -10.1%. On the balance sheet: a debt-to-equity ratio of 0.42 and a current ratio of 14.46. Over the past 52 weeks the share price ranged from $13.18 to $34.29, with a beta of 0.96.
Viridian Therapeutics, Inc. does not currently pay a dividend.
17 Wall Street analyst ratings cover the stock: 15 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Viridian Therapeutics, Inc. (VRDN) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 9.59% / 30% · (Cash+Inv) / Mkt Cap (36m) 37.8% / 30% · Interest income / Revenue 37.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 9.59% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 37.8% / 33% · Receivables / Mkt Cap (36m) 1.18% / 49% · Interest income / Revenue 37.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 9.59% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 37.8% / 33.33% · Receivables / Mkt Cap (24m) 1.18% / 33.33% · Interest income / Revenue 37.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 15.4% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 93.7% / 33.33% · Receivables / Avg Assets (4Q) 2.75% / 33.33% · Interest income / Revenue 37.0% / 5% | Fail |
| FTSE | Debt / Total Assets 23.6% / 33.33% · (Cash+ST Inv) / Total Assets 92.9% / 33.33% · (Cash+Recv) / Total Assets 95.8% / 33.33% · Interest income / Revenue 37.0% / 5% | Fail |
No. As of September 2026, Viridian Therapeutics, Inc. (VRDN) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Viridian Therapeutics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 37.0% of each dividend: Viridian Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.